Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
Portfolio Pulse from
Phio Pharmaceuticals has completed enrollment for the third safety cohort in its Phase 1b study of PH-762, a therapeutic using INTASYL® siRNA technology to enhance immune cell effectiveness against cancer.
March 05, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals has completed enrollment for the third safety cohort in its Phase 1b study of PH-762, a therapeutic using INTASYL® siRNA technology to enhance immune cell effectiveness against cancer.
The completion of enrollment in the third safety cohort is a significant milestone in the clinical development of PH-762, indicating progress in the study. This could positively impact investor sentiment and the stock price as it shows advancement in their lead compound's development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100